Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biodynamics Plc LSE:OBD London Ordinary Share GB00BD5H8572 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.15 1.1% 13.80 51,502 16:35:11
Bid Price Offer Price High Price Low Price Open Price
13.10 14.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.34 -7.63 -7.20 14
Last Trade Time Trade Type Trade Size Trade Price Currency
16:11:41 O 10,000 13.90 GBX

Oxford Biodynamics (OBD) Latest News (3)

More Oxford Biodynamics News
Oxford Biodynamics Investors    Oxford Biodynamics Takeover Rumours

Oxford Biodynamics (OBD) Discussions and Chat

Oxford Biodynamics Forums and Chat

Date Time Title Posts
05/7/202208:53Oxford BioDynamics PLC441
17/2/202211:29OBD-23/03/21-110P-SP might go up exponentially given the potential in the US12

Add a New Thread

Oxford Biodynamics (OBD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Oxford Biodynamics trades in real-time

Oxford Biodynamics (OBD) Top Chat Posts

Oxford Biodynamics Daily Update: Oxford Biodynamics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OBD. The last closing price for Oxford Biodynamics was 13.65p.
Oxford Biodynamics Plc has a 4 week average price of 12p and a 12 week average price of 12p.
The 1 year high share price is 62.80p while the 1 year low share price is currently 12p.
There are currently 100,351,574 shares in issue and the average daily traded volume is 344,037 shares. The market capitalisation of Oxford Biodynamics Plc is £13,848,517.21.
mint1111: I've been looking at the webinar and the product looks ok but very little sold. The share price has fallen greatly and there's talk of a new issue. I'm going to wait and see what happens after before I buy any.
yellowstoneadvisory: There is also a write up of the recent webinar on which OBD talk about how pleased they are with the way they are raising awareness for CiRT, initial orders and the potential to come. The product meets a clear medical need and brings significant benefits to patients, oncologists and payors. There are currently six big pharma companies negotiating possible contracts and the first high-volume contracts are expected soon. There is a lot of hard work to be done but the team are all pulling in the same direction. You can read the full write up here Https://
multibagger: Good morning all :) An exciting scientific development with loads of potential, but ability of OBD to commercialise on a meaningful scale remains suspect, till proof to the contrary IMHO. The could be hope that at some point OBD is bought for its IP but till then the market is unlikely to pay attention to companies burning cash at a rate of knots. Revenues are what make the difference....
badger60: It's all about revenue, and OBD isn't making any, but incurring substantial ongoing cashburn. Look at the OBD 52 week high and low share price The market rarely lies.....80p down to 16p..... currently trading at 17p....and the long term graph is totally abysmal. There will be a fundraiser without doubt, and depending on how much cash is currently left, they may need to do it soon to qualify as still being a going concern. Orders, presentations and enquiries etc. are all well and good.....Show me the far more important....
jimtech: Dr Jon Burrows, CEO of OBD, said: "Since the February 25th launch, we have seen positive early traction for our test, with five initial orders for the test in March and 17 test orders in April by four different oncology groups. This is very encouraging engagement from early adopters with respect to an innovative and new genomic platform technology. This growing early adoption is promising, and oncologist feedback is positive."
badger60: The wheels continue to fall off here as Vulpes 17% OBD shareholding, which is not mentioned on their web site, takes another share price hit.The cash burn here is horrendous with no income to support it so funding is desperately needed soon, imo. Where's it going to come from?
stocktastic: The share price here smells of fundraiser to me. I havent looked at cash levelz Might OBD be looking to raise funds? Any views on competitors for this checkpoint inhibitor test? I havent heard of any... but havent looked And how much data does OBD have? I'd want to know how well it works by PDL1 level for example ...and what about in combinations. Can the test firmly show patients who would be better off with another therapy. If not, I cant see the test being used
boonkoh: Fascinating that Armistice sold. At a big loss. Does anyone know if they were forced sellers? Over leveraged on other positions and needing cash?I still think there is nothing in danger with the CIRT validation, just that it is delayed. If there was something wrong, then the directors wouldn't have bought shares over the past two months. Why throw good money away, and there has been no "incentive" to keep the share price high atm (ie bonus scheme dependent on share price at a certain date).The amount of shares bought by directors seem low but they're not insignificant either. Overall, a mixed bag but I'm for now still holding.
badger60: Dear oh dear...not looked in here for some time but the share price was well into 3 figures...maybe even's happened???Another death by Diggle share. What with PRM, and Oxb seriously nosediving......OBD must be doing a PRM deja vu.PRM peaked at 240pps in 2003... currently "trading" at 4 and a bit p..... Looks like OBD is running down the same railroad track.Still....who gives a Diggle.....
rambutan2: Interesting, and fairly welcome developments, as US hedge fund sees value and buys in: Oxford, UK - 25 October 2021 - Oxford BioDynamics Plc (AIM: OBD, "OBD", "the Company" and, together with its subsidiaries, "the Group"), a biotechnology company developing targeted clinical diagnostic tests for immune health using its EpiSwitch(R) 3D genomics technology, announces that it has raised GBP3.62 million (US$ 5 million) by way of a Subscription for 7,791,803 newly-issued ordinary shares of 1p each (the "Subscription Shares"), from leading US-based healthcare fund, Armistice Capital Master Fund Ltd ("Armistice Capital") at a price of 46.5 pence per Subscription Share ("Subscription Price"). In addition, the Company has agreed to issue Armistice Capital 7,791,803 warrants to subscribe for new ordinary shares ("Warrants"). The Warrants have an exercise price of 58.125 pence, representing a 25 per cent. premium to the Subscription Price. Key features of the Subscription and Warrants -- The Subscription Price of 46.5 pence per New Ordinary Share is equal to the closing mid-market price on 22 October 2021 -- The 7,791,803 Subscription Shares have been issued under existing shareholder authorities and represent 8.42% of the issued share capital immediately before the Subscription -- The Company will also issue to Armistice Capital, conditional on the approval of shareholders in a General Meeting, warrants to subscribe for 7,791,803 new ordinary shares. The Warrants are exercisable for cash between one and five years from the date of issue. hTtp:// htTps:// htTPs://
Oxford Biodynamics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220705 22:04:18